Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 8, 26 | Boehnlein Glenn S | director | A-Award | 817 @ $146.85 | $120.0K |
Daily · Wilder smoothing
| Sep 4, 26 |
| Boehnlein Glenn S |
| director |
| 0 |
| — |
| Sep 4, 26 | Boehnlein Glenn S | director | 0 | — |
| Sep 4, 26 | Dolsten Mikael | director | S-Sale | 634 @ $151.38 | $95.97K |
| Jun 26, 26 | Kirkwood Jonah Prevost | officer: Senior Vice President | F-InKind | 30 @ $136.01 | $4.08K |
| Jun 2, 26 | Downs Timothy Charles | officer: VP, Chief Accounting Officer | 0 | — |
| Jun 3, 26 | Mcdonnell Padraig | director, officer: President and CEO | F-InKind | 418 @ $137.40 | $57.43K |
| May 29, 26 | Dolsten Mikael | director | S-Sale | 1,600 @ $135.42 | $216.7K |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 54.73 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 71.95 | Oscillator | Neutral |
| Williams %R (14) | -48.04 | Oscillator | Neutral |
| MACD (12, 26, 9) | 3.64 (Hist -0.60) | Oscillator | Sell |
| Average Directional Index (14) | 36.27 (+DI 25.9 / -DI 14.2) | Trend | Strong Buy |
| EMA 20 | 170.42 | MA | Buy |
| SMA 20 | 171.85 | MA | Sell |
| EMA 50 | 162.03 | MA | Strong Buy |
| SMA 50 | 161.38 | MA | Strong Buy |
| SMA 200 | 135.27 | MA | Strong Buy |
Stock news · updated daily
SANTA CLARA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Proscia®, a provider of digital pathology software for clinical and life-sciences customers, in an all-cash transaction valued at $240 million in cash at closing and up to an additional $30 million based on achieving future performance milestones. Proscia is a leading independent provider of enterprise digital pathology software, serving.
Here is how Agilent Technologies (A) and Concentra Group (CON) have performed compared to their sector so far this year.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the NovoStation Sample Preparation System, a new automated platform designed to help laboratories simplify and streamline flow cytometry sample preparation. When paired with a NovoCyte flow cytometer and NovoExpress software, NovoStation offers an integration-ready solution that enables a hands-free sample-to-answer workflow, helping scientists spend less time preparing samples and more time.
On September 30, 2026, we present a DCF analysis for Agilent Technologies Inc (A), a company that has shown robust price performance with a year-to-date increas
Shares of Agilent Technologies, Inc. (NYSE: A - Get Free Report) hit a new 52-week high during mid-day trading on Monday. The company traded as high as $174.77 and last traded at $174.67, with a volume of 488742 shares. The stock had previously closed at $172.79. Wall Street Analysts Forecast Growth A number of brokerages recently
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent BioTek Gen5 AI cell identification module, a new image analysis software add-on that incorporates AI-based cell identification and segmentation into BioTek Gen5 imaging analysis. Developed for use with compatible Agilent BioTek automated imaging systems, the module uses AI-based segmentation without requiring conventional threshold setting or parameter tuning. By incorporating the.
Shares of Agilent Technologies, Inc. (NYSE: A - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty research firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 26, 2026 | 1.49 | 1.62 | Beat 8.7% | $1.88B |
| May 27, 2026 | 1.41 | 1.49 | Beat 5.7% | $1.83B |
| Feb 25, 2026 | 1.37 | 1.36 | Miss -0.7% | $1.80B |
| Nov 24, 2025 | 1.58 | 1.59 | Beat 0.4% | $1.84B |
| Aug 27, 2025 | 1.37 | 1.37 | Beat 0.0% | $1.74B |
| May 28, 2025 | 1.26 | 1.31 | Beat 4.0% | $1.67B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| EFFECT | Sep 23, 2026 | 2026-09-24 00:15:03 | View |
| 424B3 | Sep 23, 2026 | 2026-09-23 16:45:21 | View |
| 4 | Sep 10, 2026 | 2026-09-10 08:52:22 | View |
| 3 | Sep 10, 2026 | 2026-09-10 08:48:42 | View |
| 4 | Sep 9, 2026 | 2026-09-09 16:01:41 | View |
| 8-K | Sep 8, 2026 | 2026-09-08 08:15:13 | View |
| S-4 | Sep 1, 2026 | 2026-09-01 17:16:10 | View |
| S-3ASR | Sep 1, 2026 | 2026-09-01 17:11:49 | View |
| 10-Q | Sep 1, 2026 | 2026-09-01 16:11:15 | View |
| 8-K | Aug 26, 2026 | 2026-08-26 16:06:25 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | A | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 33.7x | 31.6x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 27.9x | EPS est. 6.20 | Discount |
| Price / Book | 6.6x | 6.9x | In line |
| Price / Sales | 6.6x | 6.0x | In line |
| EV / EBITDA | 24.8x | 22.7x | In line |
| Return on equity | 20.5% | — | Top tier |
| Gross margin | 53.7% | 53.1% | In line |
| Debt / Equity | 0.54 | 0.52 | Moderate |
| Piotroski / Altman Z | 6/9 | Z 5.90 | Safe zone |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Current price $173.07
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 13, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Oct 13, 26 | TD Cowen | maintain | Buy | Buy |
| Oct 7, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 28, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Aug 27, 26 | Goldman Sachs | maintain | Buy | Buy |
| Aug 27, 26 | Citigroup | maintain | Buy | Buy |
| Aug 27, 26 | B of A Securities | maintain | Buy | Buy |
| Aug 27, 26 | Stifel | maintain | Buy | Buy |
| Aug 27, 26 | Barclays | maintain | Overweight | Overweight |